iPS细胞的遗传安全性

自2006年Takahashi和Yamanaka首次成功地从小鼠成纤维细胞诱导得到诱导多能性干细胞(Induced pluripotent stem cells, iPS细胞)以来, iPS细胞由于其潜在的广阔应用前景而迅速成为干细胞研究领域的新热点; 与此同时, iPS细胞的遗传安全性也越来越多地受到人们的关注。文章将对iPS细胞遗传安全性的研究进展进行综述, 分析造成iPS细胞遗传不稳定的可能原因, 希望可以促进对iPS细胞诱导条件的优化, 获得遗传上较为安全的iPS细胞。     

《自然-生物技术》：不同体细胞来源iPS细胞安全性存差异

日本研究人员在新一期《自然-生物技术》杂志上报告说,动物实验证明。用不同种类的体细胞培育出的诱导多功能干细胞（iPS）移植后使实验鼠出现肿瘤的危险性存在很大差异。     

诱导性多潜能干细胞(iPS细胞)的研究进展

通过转染特定的基因组合可以将已分化的体细胞重编程为多潜能干细胞,这种干细胞称为诱导性多潜能干细胞(induced pluripotent stem cells,iPS cells)。这是近年来干细胞研究领域最令人瞩目的一项新的干细胞制备技术。iPS细胞的出现不仅为体细胞重编程去分化机制的研究提供了新的模型,而且为疾病发生发展相关机制研究与特异的细胞治疗带来了新的希望。就当前获取iPS细胞的方法、影响iPS细胞转化率和多能性维持的一些因素及其研究进展进行综述。     

人iPS细胞和人ES细胞的研究及实用化

从首次报道算起不过一年半的时间iPS细胞制品就在市场上出现了。美国已经批准人ES进入临床试验,日本的政策有所放宽。为了利用迄今谜团甚多的iPS细胞和ES细胞,基础研究是必要的。     

iPS细胞:一种肿瘤细胞

诱导多能干细胞(iPS细胞)可以用于定向分化、动物发育、药物筛选和疾病治疗等研究和应用领域,可以避免ES细胞产生的免疫排斥和伦理道德问题.因此,iPS细胞的产生具有里程碑的意义,并迅速成为生物科学领域中的研究热点.然而,iPS细胞并非非常完美,没有任何瑕疵.研究过程中发现iPS细胞存在诱导频率过低、致瘤性、临床应用安全等一系列问题.本文主要综述有关iPS细胞前期研究成果和iPS细胞存在的一些问题以及iPS细胞与肿瘤细胞之间的联系.     

《自然-细胞生物学》：一表观遗传学因子促进iPS细胞生成

近日,来自北卡罗莱纳大学莱恩伯格综合癌症中心的研究人员揭示了一个在体细胞重编程中扮演重要角色的表观遗传学因子及其分子作用机制。     

iPS细胞的制备者——山中伸弥

iPS细胞是一种通过转入特定基因而将体细胞诱导出来的干细胞,拥有全能性,在治疗器官衰竭或坏死方面具有巨大潜力。2006年,日本科学家山中伸弥首次将小鼠成纤维细胞转入4个转录因子而制备成功iPS细胞,随后利用相似方法还获得人的iPS细胞．证明了这个方法的可行性。iPS细胞的发明从根本上改变了发育生物学领域的研究,为许多疾病的治疗带来了新的希望。通过介绍山申伸弥及iPS细胞的制备过程,对iPS发明历史有一个轮廓性的认识。     

MNNG诱发的遗传不稳定vero细胞中错配修复功能的研究

Gel retardation analysis and in vitro DNA mismatch repair system were used to examine whether there were mismatch repair deficiency in MNNG-induced genetically unstable vero cell, which was manifested by a delayed and highly increased rate of non-targeted mutation. A mismatch binding protein which could selectively bind to G.T mispair in DNA was identified in its whole-cell extracts. It was also identified that G.T mispair could be specifically and effectively corrected into G.C pair in its nuclear extracts. Compared with normal vero cell, there were no functional deficiency of the above mismatch repair mechanisms. So it could be excluded the possibility that the functional deficiency of mismatch binding protein or G.T mismatch repair pathway participated in the induction of genetic instability in vero cell by MNNG.     

细胞重编程中的表观遗传分子机制

成体细胞可以通过核移植、细胞融合或者特定因子导入的方式实现重编程回到多能性状态。在重编程的过程中,表观遗传水平的调控机制起到了非常关键的作用。通过回顾重编程的研究进展来探讨表观遗传学在重编程中的调控机制。     

慢病毒直接诱导形成猪iPS细胞无需限定因子

为了证实慢病毒对细胞具有遗传修饰和重编程作用,在本实验中使用慢病毒感染猪胎儿成纤维细胞.结果显示:慢病毒介导的EGFP在猪胎儿成纤维细胞中稳定和高效表达,使用添加LIF和bFGF的细胞培养液,部分猪的胎儿成纤维细胞逐渐改变原有的纤维状形态,形成圆形的细胞,细胞逐步增殖形成细胞集落,细胞集落边界清晰,在饲养层上细胞集落生长迅速,具有稳定的生长性能和正常核型,细胞碱性磷酸酶染色为阳性,表达干细胞特有的标记Oct4、Nanog和SSEA1,在体外能够形成拟胚体,在体内分化形成包含三个生殖层的畸胎瘤.作为核移植的供体细胞,克隆胚的卵裂率为53.33%、桑椹胚率为9.03%、囊胚率为2.07%、孵化囊胚的总细胞数为26.5,在桑椹胚率和囊胚率方面显著低于猪普通胎儿成纤维细胞核移植克隆胚的发育能力(P<0.05).结果证实慢病毒能够直接使猪的胎儿成纤维细胞转变成iPS细胞,因此慢病毒将成为一种理想的材料和工具用于细胞的遗传修饰和细胞重构等方面的研究.     

The applications of induced pluripotent stem (iPS) cells in drug development

The introduction of induced pluripotent stem (iPS) cells has been a milestone in the field of regenerative medicine and drug discovery. iPS cells can provide a continuous and individualized source of stem cells and are considered to hold great potential for economically feasible personalized stem cell therapy. Various diseases might potentially be cured by iPS cell-based therapy including Parkinson’s disease, Alzheimer’s disease, Huntington disease, ischemic heart disease, diabetes and so on. Moreover, iPS cells derived from patients suffering from unique incurable diseases can be developed into patient- and disease-specific cell lines. These cells can be used as an effective approach to study the mechanisms of diseases, providing useful tools for drug discovery, development and evaluation. The development of suitable methods for the culture and expansion of iPS cells and their differentiated progenies make feasible modern drug discovery techniques such as high-throughput screening. Furthermore, iPS cells can be applied in the field of toxicological and pharmacokinetics tests. This review focuses on the applications of iPS cells in the field of pharmaceutical industry.     

诱导多能干细胞(iPS)的诱导培养与鉴定

通过外源转录调控因子的诱导,使成体细胞重编程为胚胎干细胞(ES细胞)样的多能细胞,这种细胞称为诱导多能干细胞(iPS细胞),这一方法被称为iPS技术。目前,iPS技术已先后在小鼠、人、猕猴、大鼠和猪中成功应用,建立了相应的iPS细胞系,并获得了iPS细胞嵌合小鼠和四倍体克隆小鼠。尽管iPS与ES细胞在形态和生长特性上有许多相同之处,但iPS细胞的建立需要较独特的诱导培养体系和鉴定方法。以下结合近年来iPS技术的发展和本实验室的相关研究,对iPS细胞的建立和培养体系的优化进行了深入探讨。     

The genomic stability of induced pluripotent stem cells

With their capability to undergo unlimited self-renewal and to differentiate into all cell types in the body, induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells of human patients with defined factors, hold promise for regenerative medicine because they can provide a renewable source of autologous cells for cell therapy without the concern for immune rejection. In addition, iPSCs provide a unique opportunity to model human diseases with complex genetic traits, and a panel of human diseases have been successfully modeled in vitro by patient-specific iPSCs. Despite these progresses, recent studies have raised the concern for genetic and epigenetic abnormalities of iPSCs that could contribute to the immunogenicity of some cells differentiated from iPSCs. The oncogenic potential of iPSCs is further underscored by the findings that the critical tumor suppressor p53, known as the guardian of the genome, suppresses induced pluripotency. Therefore, the clinic application of iPSCs will require the optimization of the reprogramming technology to minimize the genetic and epigenetic abnormalities associated with induced pluripotency.     

Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells

Evaluation of antiangiogenic activity of marine sponge derived azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells was carried out. Azumamide E (5) strongly inhibited in vitro angiogenesis from iPS cells at 1.9 μM while azumamide A (1) showed only weak inhibition at 19 μM. These results were well correlated with HDAC inhibitory activity of these compounds, revealing the prospect of azumamides as the probe molecules useful for stem cell chemical biology.     

诱导性多潜能干细胞技术进展

诱导性多潜能干细胞(induced pluripotent stem cells,iPSCs)可以通过在分化的成纤维细胞中导入特定的转录因子获得。IPS细胞与胚胎干细胞(embryonic stem cell,ESCs)在形态,增殖能力,基因表达谱和畸胎瘤形成上没有区别,因此在研究疾病机制,药物筛选和毒理学上有重要的应用价值。一旦解决了安全性和效率问题,iPS细胞将在再生医学上有重要的应用价值。主要从提高转化效率、制备无遗传修饰的iPS细胞和疾病特异性的iPS细胞这3个近来在iPS领域飞速进展的方向做一综述。     

Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs)

Introduction

(1) Human embryonic stem (ES) cells are pluripotent but are difficult to be used for therapy because of immunological, oncological and ethical barriers. (2) Pluripotent cells exist in vivo, i.e., germ cells and epiblast cells but cannot be isolated without sacrificing the developing embryo. (3) Reprogramming to pluripotency is possible from adult cells using ectopic expression of OKSM and other integrative and non-integrative techniques. (4) Hurdles to overcome include i.e stability of the phenotype in relation to epigenetic memory.

Sources of data

We reviewed the literature related to reprogramming, pluripotency and fetal stem cells.

Areas of agreement

(1) Fetal stem cells present some advantageous characteristics compared with their neonatal and postnatal counterparts, with regards to cell size, growth kinetics, and differentiation potential, as well as in vivo tissue repair capacity. (2) Amniotic fluid stem cells are more easily reprogrammed to pluripotency than adult fibroblast. (3) The parental population is heterogeneous and present an intermediate phenotype between ES and adult somatic stem cells, expressing markers of both.

Areas of controversy

(1) It is unclear whether induced pluripotent stem (iPS) derived from amniotic fluid stem cells are fully or partially reprogrammed. (2) Optimal protocols to ensure highest efficiency and phenotype stability remains to be determined. (3) The “level” of reprogramming, fully vs partial, of iPS derived from amniotic fluid stem cells remain to be determined.

Growing points

Banking of fully reprogrammed cells may be important both for (1) autologous and allogenic applications in medicine, and (2) disease modeling.     

The first reported generation of human induced pluripotent stem cells (iPS cells) and iPS cell-derived cardiomyocytes in the Netherlands

One of the recent breakthroughs in stem cell research has been the reprogramming of human somatic cells to an embryonic stem cell (ESC)-like state (induced pluripotent stem cells, iPS cells). Similar to ESCs, iPS cells can differentiate into derivatives of the three germ layers, for example cardiomyocytes, pancreatic cells or neurons. This technique offers a new approach to investigating disease pathogenesis and to the development of novel therapies. It may now be possible to generate iPS cells from somatic cells of patients who suffer from vascular genetic diseases, such as hereditary haemorrhagic telangiectasia (HHT). The iPS cells will have a similar genotype to that of the patient and can be differentiated in vitro into the cell type(s) that are affected in the patient. Thus they will serve as excellent models for a better understanding of mechanisms underlying the disease. This, together with the ability to test new drugs, could potentially lead to novel therapeutic concepts in the near future. Here we report the first derivation of three human iPS cell lines from two healthy individuals and one HHT patient in the Netherlands. The iPS cells resembled ESCs in morphology and expressed typical ESC markers. In vitro, iPS cells could be differentiated into cells of the three germ layers, including beating cardiomyocytes and vascular cells. With this technique it will be possible to establish human cardiovascular disease models from patient biopsies provided by the principal hospitals in the Netherlands. (Neth Heart J 2010;18:51-4.)